Market Research Logo

Sudan Pharmaceuticals and Healthcare Report Q4 2017

Sudan Pharmaceuticals and Healthcare Report Q4 2017

BMI View:

The business environment in Sudan will remain decidedly difficult for multinational pharmaceutical companies. While the lifting of several US sanctions on Sudan will benefit the economy, a combination of high inflation, poor consumer spending and political fragilities will undermine the pace of pharmaceutical market growth. The government's plans to improve domestic pharmaceutical manufacturer capabilities will attempt to reduce ongoing medicine shortages; however, we do not expect self-sufficiency to be achieved over the short-to-medium term.

Headline Expenditure Projections

Pharmaceuticals: SDG3.26bn (USD544mn) in 2016 to SDG3.55bn (USD546mn) in 2017; +8.7% in local currency terms and +0.3% in US dollar terms. Forecast in line with previous quarter.

Healthcare: SDG33.6bn (USD5.60bn) in 2016 to SD36.2bn (USD5.57bn) in 2017; +7.7% in local currency terms and -0.6% in US dollar terms. Forecast in line with previous quarter.

Risk/Reward Index

Sudan represents a high-risk, low-reward pharmaceutical market, compounded by a host of industryassociated risks and a challenging business environment for innovative drugmakers, as reflected in its score of 21.5 out of 100 in BMI's Innovative Pharmaceuticals Risk/Reward Index. While Sudan's medicine expenditure is relatively large on a regional basis, the pharmaceutical market suffers from poor regulation and low per-capita medicine expenditure, perpetuating a highly challenging environment for patented drugmakers.


BMI Industry View
Table: Headline Pharmaceuticals And Healthcare Forecasts (Sudan 2015-2021)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Sudan 2013-2021)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2013-2021)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2013-2021)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Sudan 2013-2021)
Industry Risk/Reward Index
Sub-Saharan Africa Pharmaceuticals: Small Market Sizes Weaken Attractiveness To Innovative Drugmakers
Innovative Pharmaceuticals Risk/Reward Index - Sudan - Q4 2017
Regulatory Review
Intellectual Property Issues
Pricing And Reimbursement Regime
Market Overview
Healthcare Sector
Research & Development
Clinical Trials
Epidemiology
Competitive Landscape
Research-Based Industry
Table: Multinational Market Activity
Generic Drugmakers
Demographic Forecast
Sudan Demographic Forecast
Table: Population Headline Indicators (Sudan 1990-2025)
Table: Key Population Ratios (Sudan 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Sudan 1990-2025)
Table: Population By Age Group (Sudan 1990-2025)
Table: Population By Age Group % (Sudan 1990-2025)
South Sudan Demographic Forecast
Table: Population Headline Indicators (South Sudan 1990-2025)
Table: Key Population Ratios (South Sudan 1990-2025)
Table: Urban/Rural Population & Life Expectancy (South Sudan 1990-2025)
Table: Population By Age Group (South Sudan 1990-2025)
Sudan & South Sudan Pharmaceuticals & Healthcare Report Q4 2017
© Business Monitor International Ltd Page 4
Table: Population By Age Group % (South Sudan 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Table: Indicators - Rationale And Sources

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report